Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
SAN DIEGO—Peter C. Farrell, Chairman Emeritus of ResMed Inc . (NYSE:RMD), recently sold 2,000 shares of the company’s common stock. The transaction, disclosed in a Form 4 filing with the Securities and Exchange Commission, took place on March 5, 2025, at an average price of $227.71 per share, amounting to a total value of $455,420. The sale comes as ResMed, a $33 billion market cap healthcare company, maintains a perfect Piotroski Score of 9 and an overall GREAT financial health rating, according to InvestingPro analysis.
Following this sale, Farrell retains ownership of 75,218 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan, which was adopted on May 28, 2024. ResMed, a leader in the field of medical instruments and apparatus, continues to be a significant player in the healthcare industry, with 9.38% revenue growth and trading slightly below its Fair Value. Discover more insights and 12 additional ProTips about RMD with an InvestingPro subscription.
In other recent news, ResMed reported its Q2 FY2025 earnings, surpassing analyst expectations with an earnings per share (EPS) of $2.43, compared to the forecasted $2.32. The company also exceeded revenue projections, posting $1.28 billion against the anticipated $1.27 billion. Despite these strong earnings, ResMed’s stock experienced a decline in after-hours trading. Citi analysts upgraded ResMed shares from Neutral to Buy, increasing the price target to AUD44.00, highlighting the company’s expected strong EPS growth and robust free cash flow. Meanwhile, Stifel analysts adjusted their outlook on ResMed, reducing the price target to $240 from $250, due to potential challenges in the CPAP market related to the growing use of GLP-1 drugs. ResMed was also added to Goldman Sachs’ APAC Director’s Cut Conviction List, with expectations of strong patient growth in Continuous Airway Pressure Therapy and market share expansion. These recent developments reflect a mix of optimism and caution among analysts regarding ResMed’s future market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.